Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05479812 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Werewolf Therapeutics.

Active
Registry status
Phase 1
Development phase
150
Enrollment target
14
Study locations

NCT05479812 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is active but no longer recruiting, run by Werewolf Therapeutics. The registered enrollment target is 150 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The trial reports 14 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05479812, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is active but no longer recruiting, sponsored by Werewolf Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
14
Study locations

Study Summary

A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor

Interventions

  • DRUG pembrolizumab
  • DRUG WTX-124

Study Locations (14)

Texas

  • Texas Oncology - Austin Midtown - Austin
  • University of Texas Southwestern Medical Center - Dallas
  • NEXT Oncology - Houston
  • NEXT Oncology - San Antonio

New York

  • Roswell Park Comprehensive Cancer Care - Buffalo
  • Westchester Medical Center - Hawthorne

Arizona

  • HonorHealth - Scottsdale

Florida

  • Moffitt Cancer Center - Tampa

Georgia

  • Emory Winship Cancer Institute - Atlanta

Illinois

  • Northwestern University - Chicago

Indiana

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis

Minnesota

  • Minnesota Oncology Hematology, P.A. - Maple Grove

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-05-20
Est. Completion 2026-07-31
Phase Phase 1

Sponsor

Werewolf Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05479812

The ClinicalTrials.gov registry entry for NCT05479812 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% lower). The listed sponsor is Werewolf Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.

NCT05479812 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Texas, New York, Arizona.

Frequently Asked Questions

What is clinical trial NCT05479812 about?

NCT05479812 is a clinical study titled "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors". A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.

What is the current status of trial NCT05479812?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2022-05-20. Estimated completion is 2026-07-31.

What conditions does trial NCT05479812 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.

What interventions are being tested in trial NCT05479812?

The interventions under investigation include: pembrolizumab (DRUG), WTX-124 (DRUG).

Who is sponsoring clinical trial NCT05479812?

This trial is sponsored by Werewolf Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05479812 being conducted?

This trial has 14 study locations across Arizona, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Metastatic Solid Tumor

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.